Momentis Surgical

What Momentis Surgical does

Momentis Surgical, founded in 2013 in Or Yehuda, Israel (with US headquarters in Fort Lauderdale, Florida), develops and commercializes the Anovo Surgical System — a miniaturized, two-armed robotic platform with humanoid-shaped arms featuring shoulder, elbow, and wrist joints designed to replicate the full range of surgeon motion. The system received FDA De Novo marketing authorization in February 2021 for robotic-assisted transvaginal benign gynecological procedures, including hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal, and secured an additional 510(k) clearance extending into general surgery. The 13-pound Robotic Control Unit, open console, and single-port transvaginal access are positioned as a lower-cost, smaller-footprint alternative to incumbent multi-port robotic platforms, enabling adoption in ambulatory surgery centers and mid-sized hospitals.

The company monetizes primarily through capital-equipment sales of the Anovo Surgical System to US hospitals and ambulatory surgery centers, supplemented by service contracts, training (via Momentis University), and consumables. It runs an enterprise field-sales motion targeting hospital C-suites and key opinion leader surgeons, with the largest customer concentration at HCA Healthcare facilities. As of late 2022, named adopters included multiple HCA sites, Lee Health's Gulf Coast Medical Center, Medical City Plano (first Texas install), and The Women's Hospital at Jackson Memorial. The company is led by co-founder and CEO Dvir Cohen, with Dr. Maurice Ferré (founder of MAKO Surgical) as Chairman and Dr. Fred Moll (co-founder of Intuitive Surgical) as a board member. Total disclosed funding exceeds $116M, anchored by a $96M Series D in 2021.

The business is venture-backed and privately held, holding 16 US and 140 global patents covering the mechanical-arm architecture, articulation controllers, and transvaginal access tools. Strategic priorities evident in recent activity include: scaling US hospital adoption under the HCA anchor, expanding into the general-surgery indication post-510(k) clearance, and building clinical-evidence and surgeon-training infrastructure to support broader procedural adoption.

Name

Momentis Surgical

Legal name

Momentis Innovative Surgery Ltd.

Website

https://momentissurgical.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Momentis Surgical develops the Anovo Surgical System, a miniaturized two-armed robotic platform for transvaginal benign gynecological and general surgery procedures, selling capital systems to US hospitals and ambulatory surgery centers with an enterprise field-sales model.

Ownership category

akta.pro rank

Product category

Surgical Robotics

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industries

Healthcare & Assistive Robotics (HDAAAIAC), Surgical Navigation, Robotics & Patient-Matched Instrumentation (Ortho/Spine) (HLAHAEAL)

Keywords

• Surgical robotics
• Minimally invasive surgery
• Robotic-assisted surgery
• Gynecological surgery
• Transvaginal surgery

Headquarters

HQ city

Or Yehuda

HQ country

Israel

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Anovo Surgical System Sales: Sale of the Anovo Surgical System hardware to hospitals and ambulatory surgery centers. The system requires significantly lower cost than conventional robotic systems, enabling broader adoption across healthcare facilities. Revenue generated from initial system sale plus ongoing service, training, and consumables.
2. Service and Support: Ongoing service contracts, training programs, and support for installed base of Anovo Surgical Systems at hospital customers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Momentis Surgical develops, manufactures, and commercializes the Anovo Surgical System, a miniaturized humanoid-arm robotic surgical platform featuring two articulated arms with shoulder, elbow, and wrist joints that mimic surgeon movements for minimally invasive transvaginal benign gynecological procedures. The system includes a compact Robotic Control Unit (RCU), surgeon console, instrument arms, and vaginal access kit, sold with associated training and service to hospitals and ambulatory surgery centers.

Product overview

Momentis Surgical offers the Anovo Surgical System as its primary product — a miniature humanoid-arm robotic surgical platform designed for minimally invasive transvaginal benign gynecological procedures. The system consists of the Anovo Robotic Control Unit (RCU), Anovo Surgeon Console, Anovo Instrument ARMS with vaginal access kit, and Momentis University for surgeon training. Previously marketed as the Hominis Surgical System before the company's July 2022 rebrand from Memic Innovative Surgery to Momentis Surgical. The Anovo system was granted FDA De Novo authorization in February 2021 and received additional FDA 510(k) clearance for general surgery in 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Anovo Surgical System: The proprietary surgical robotic system featuring miniature humanoid-shaped arms with shoulder, elbow, and wrist joints for minimally invasive transvaginal surgery.

Products and services

• Anovo Surgical System Miniature humanoid-arm robotic surgical platform featuring a 2-armed system with shoulder, elbow, and wrist joints that mimic surgeon movements, enabling transvaginal benign gynecological procedures (hysterectomy, salpingectomy, oophorectomy, adnexectomy, ovarian cyst removal). Sold to hospitals and ambulatory surgery centers, with an expanded FDA 510(k) clearance for general surgery applications.
• Momentis University Online professional training and education platform for healthcare professionals to learn about and become certified on the Anovo Surgical System.

Quantifiable outcome

• FDA authorized for benign hysterectomy, salpingectomy, oophorectomy, adnexectomy, and ovarian cyst removal via transvaginal approach
• +2 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship and core.

• HCA HealthcareflagshipStrategic or Co-development PartnerMultiple HCA Healthcare hospitals (HCA Florida Northwest Hospital, HCA Oviedo Medical Center, HCA Florida Kendall Hospital) have adopted the Anovo Surgical System. HCA represents the company's primary commercial launch partners with multiple facilities implementing the technology.
• Lee HealthcoreStrategic or Co-development PartnerLee Health (Gulf Coast Medical Center) adopted Anovo Surgical System for robotic-assisted benign gynecological surgeries. Represents company's commercial expansion in Florida market.
• Medical City PlanocoreStrategic or Co-development PartnerFirst adoption of Anovo Surgical System in Texas. Medical City Plano is the first medical facility in Texas to implement the technology for transvaginal benign gynecological procedures.
• The Women's Hospital at Jackson MemorialcoreStrategic or Co-development PartnerFirst U.S. patient procedures successfully completed using the Anovo/Hominis System at this facility as part of initial commercial launch.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Large diversified medtech incumbent that has launched the Hugo robotic-assisted surgery system, competing in urology, gynecology, and general surgery. Comparable as a multi-port robotic platform entrant pursuing similar specialties as Anovo, but as part of a much broader device portfolio.
• Smith+Nephew: Markets the CORI handheld robotics platform for orthopedics alongside its broader sports medicine and ENT portfolio. Comparable as a diversified medtech incumbent with a robotic-assisted surgery offering in its portfolio.
• Stryker (MAKO Surgical): Acquired MAKO Surgical for $1.65B and markets robotic-assisted orthopedic surgery platforms. Chairman Dr. Maurice Ferré founded MAKO and now chairs Momentis, creating a leadership link and a comparable incumbent in surgical robotics.
• Johnson & Johnson (Auris Health): Acquired Auris Health (Monarch platform) and developed the Ottava robotic system to enter soft-tissue robotic surgery. Comparable as a broad incumbent pursuing robotic surgery in general surgery and gynecology, with vastly greater resources than Momentis.

Direct peers

• CMR Surgical: UK-based developer of the Versius surgical robotic system, a modular multi-port robot positioned for laparoscopic and gynecological procedures. Comparable as a smaller, single-platform robotic entrant competing against Intuitive in gynecology and general surgery.
• Intuitive Surgical: Developer of the da Vinci Surgical System, the dominant multi-port robotic surgery platform used across gynecology, urology, general surgery, and thoracic procedures globally. Intuitive is the most direct competitor to Momentis in benign gynecologic and transvaginal robotic surgery.

Emerging players

• SS Innovations: India-based developer of the Mantra surgical robotic system targeting cost-sensitive markets. Comparable as a lower-cost robotic surgery entrant pursuing emerging-market adoption with a similar value proposition to Momentis's compact, affordable Anovo platform.
• Moon Surgical: French-based developer of a compact surgical robotics assistant for laparoscopic procedures. Comparable as an early-stage European surgical robotics company pursuing the same cost-effective, compact-system positioning against da Vinci.
• Procept BioRobotics: Developer of the Aquablation and HYDRO robotic systems for benign prostatic hyperplasia treatment. Comparable as a focused surgical robotics company with a single platform serving a specific urological/gynecological adjacent indication.
• Vicarious Surgical: US-based developer of a single-port robotic surgical system with decoupled actuators designed for abdominal and gynecological procedures. Comparable as a single-port surgical robotics entrant targeting similar clinical use cases to Anovo.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Momentis Surgical